Published in final edited form as:

Tetrahedron Lett. 2008 ; 49(12): 3395–3399.

Synthesis of Fluorescent Probes based on Stilbenes and Diphenylacetylenes targeting β -Amyloid Plaques

Ajit K. Parhi, Mei-Ping Kung, Karl Ploessl, and Hank F. Kung*

Department of Radiology, University of Pennsylvania, PA 19104

Abstract

Three fluorescent probes were synthesized aiming for optical imaging to detect amyloid plaques present in patients with Alzheimer's disease (AD). These compounds were prepared via Sonogashira coupling of a well-defined fluorophore (4-bora-3a, 4a-diaza s-indacene, BODIPY) with the pharmacophore possessing either a stilbene or a diphenylacetylene moiety. Different polyethylene glycol chain lengths were used as linkers between the fluorophore and the pharmacophore to adjust the lipophilicity of these probes. These compounds exhibit strong fluorescence emission between 665–680 nm and have very high extinction coefficients comparable to the parent fluorophore, BODIPY dye.

Keywords

Fluorescent Probes; Alzheimer's disease; BODIPY; Near-IR imaging

Formation of β -amyloid (A β) plaques, consisting of β -sheets of A β protein aggregates, in the brain is a pivotal event in the pathogenesis of Alzheimer's disease (AD)^{1,2}. Thus, development of specific agents targeting A β aggregates is important for the diagnosis, and it may be possible for the evaluation of the therapeutic course of the disease progression^{3,4}. Recently, significant advancement for detection of A β plaques in AD patients has been achieved in using positron emission tomography (PET) and single photon emission tomography (SPECT) imaging ligands^{5–8}

For our effort to develop complementary techniques, we envisioned to make new water-soluble neutral fluorescent compounds that would emit in the near-infrared region and be able to bind to A β plaques as tools for *in vitro* studies. To meet the requirements of such fluorescent probes, we have employed a tether approach for designing the probes. All these fluorescent probes have three common structural units, i.e. a fluorophore, a linker and a pharmacophore, where the fluorophore is tethered to the pharmacophore through the poly(ethylene glycol) linker. The poly(ethylene glycol) linker is added to improve the water-solubility. This series of fluorescent probes are not designed to penetrate intact blood-brain barrier; instead, due to their higher molecular

*CORRESPONDING AUTHOR ADDRESS: Hank F. Kung, Ph.D., Department of Radiology, University of Pennsylvania, 3700 Market Street, Room 305, Philadelphia, PA 19104. Tel: (215) 662-3096, Fax: (215) 349-5035; e-mail: kunghf@sunmac.spect.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Data Experimental Procedure and characterization of some intermediate compounds and copies of ¹H, ¹³C and UV spectra of some intermediate compounds and all fluorescent compounds. The supplementary data is available online with the paper in scienceDirect.

weight, rather they will only bind to A β -plaques accumulated on the cerebral blood vessels, at the extravascular space, commonly observed in patients with cerebral angiopathy^{9–11}.

For all our probes prepared for this paper, we opted for the same neutral fluorophore, a 4-bora-3a, 4a-diaza s-indacene (BODIPY) dye, **1**, previously synthesized and characterized by Kim *et.al*,¹². The reason for choosing **1** as the fluorophore owes to its strong red shifted, sharp fluorescence emission at 654 nm and its neutral nature. The choice of pharmacophores is based on our previous findings that a series of 4-amino-4'-hydroxy substituted stilbene¹³ and diphenylacetylene derivatives¹⁴ showed high binding affinities (K_i = 1–10 nM range) to A β aggregates. Similarly, various units of polyethylene glycol (PEG, n = 5 or 12) as linkers on the 4'-hydroxyl group of stilbene and diphenylacetylene through which the fluorophore is attached at the end of PEG chain provides a flexible tool to adjust the lipophilicity of the dye^{15,13}. Reported herein are the synthesis and spectroscopic properties of three compounds as potential fluorescent probes targeting A β plaques.

The synthesis began with the preparation of the BODIPY dye **1** by slightly modifying the procedure reported by Kim *et.al*¹⁶. Two common methods exist to build a boradiazoindacene core: (i) starting either from an aldehyde¹⁷ or (ii) from an acyl chloride^{18,19}. In the previously reported synthesis, the dipyrromethene **4** was prepared by the condensation of 4-iodobenzoyl chloride with 2-aryl pyrrole **2**^{20,21} in a moderate yield. Although this approach is attractive owing to the acid sensitive nature of the 2-aryl pyrrole **2**, the method is hampered by its very long reaction time (usually required 2–4 days of refluxing). Therefore we decided to explore the first approach as illustrated in Scheme 1.

The condensation of p-iodobenzaldehyde with 2-aryl pyrrole **2** at 0 °C was found to be extremely fast in the presence of catalytic amounts of TFA. The corresponding dipyrromethane **3** could be isolated in 52% yield when the reaction was quenched within 5 minutes after the addition of TFA²². The subsequent oxidation to dipyrromethene **4** by p-chloroanil also proceeded rapidly²³. These two steps can be accomplished within a day in good overall yield (more than 50%). Previously, the target compound, **1**, was prepared in a one-pot two-step reaction beginning with the dipyrromethene **4**. Boron complexation of dipyrromethene **4** followed by the demethylation using BBr₃ furnished the compound **1** in 93% yield¹⁶. In a slightly modified way, we isolated the borane complex **5** and upon treatment with 1.0 M BBr₃ in DCM afforded the target dye **1** as green solid, which was identical with the reported compound in all aspects. This slight modification enabled us to use 1.0 M BBr₃ in DCM rather than neat BBr₃.

With the BODIPY dye **1** in hand, the next issue was to connect the fluorophore to the rest of molecule. Alkynyl connectors are thought to be the most appropriate because it is known that these connectors are particularly useful by favoring electronic communication and extending the conjugation length²⁴. This is especially true when the connection is through the para position of the central benzene ring of the BODIPY dye. Moreover, the iodo-substituted BODIPY dye can be suitably utilized in the cross coupling reaction with the terminal alkynes²⁵. The terminal alkynes **10a** and **10b** were prepared by reactions shown in Scheme 2.

Firstly the PEGs (n = 3 or 10) were monoalkylated with propargyl bromide to afford the terminal alkynes **7a–b** in 45% and 39% yield respectively. The free OH groups of **7a–b** were converted into mesylates **8a–b** by reacting with MsCl in the presence of triethyl amine. To prepare compounds with five or twelve ethoxy group as the PEG linkage, the mesylates **8a–b** were coupled with the OH-group of 4-methyl amino-4'-hydroxy stilbene **9**²⁶ to obtain **10a–b** in 82% and 78% yield, respectively.

In order to introduce the PEG functionalized stilbene pharmacophore into the BODIPY core, the compound **1** was coupled with the propargyl-PEG-stilbene **10a–b**.

Thus 4-iodo substituted dye **1** was treated with **10a–b** under catalyzed condition using Pd (PPh₃)₂Cl₂ and CuI, and yielded the target compounds **11a–b** in 66% and 61% yield, respectively, as green solids. These compounds were isolated via chromatography on deactivated alumina column. Extensive decomposition occurred when silica gel was used for chromatography. Similarly, the synthesis of the fluorescent compound **16** via Sonogashira coupling is shown in Scheme 4.

Palladium catalyzed coupling of alkyne **12** with 4-iodobenzaldehyde **13** produced the internal alkyne **15** in 51 % yield. Alkylation of the OH group of 4,4-dimethyl amino 4'-hydroxy diphenylacetylene **15** with the mesylate **8a** furnished the terminal alkyne **15** in 62% yield. Sonogashira coupling of **15** with **1** gave the target compound **16** in 67% yield, again as a green solid.

Spectroscopic data relevant to the present discussion are shown in Table 2. A typical fluorescence emission spectrum as shown by compound **16** is given in Figure 2.

The fluorescence properties were examined under ambient conditions either in water or in ethanol. It is important to point out that all dyes are soluble in water and exhibit the expected absorption and emission patterns typical of BODIPY dye **1**.

While compound **1** exhibits fluorescence emission at 654 nm in chloroform, all newly synthesized compounds **11a, b** and **16** are red-shifted by 10–20 nm relative to the parent compound **1**. This is probably due to the extended conjugation with the alkyne in these compounds. Compound **11a, 11b** and **16** have similar molar extinction coefficients in water ($\epsilon_{\text{max}} = 38,000 \text{ M}^{-1} \text{ cm}^{-1}$, $34,000 \text{ M}^{-1} \text{ cm}^{-1}$ and $35,000 \text{ M}^{-1} \text{ cm}^{-1}$ respectively) compared to compound **1** ($\epsilon_{\text{max}} = 46,000 \text{ M}^{-1} \text{ cm}^{-1}$) in chloroform.

In conclusion, we present here examples of water-soluble fluorescent agents with emission in the near-IR, for targeting β -amyloid plaques. These compounds were successfully prepared and characterized. They are highly water soluble and have high extinction coefficients showing emission around 665–680 nm and having higher extinction coefficients comparable to the parent fluorophore, BODIPY dye. The *in vitro* binding affinity and other biological properties of these compounds will be reported later.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by the grant from National Institutes of Health (AG-022559 to H.F.K and AG-21868 to M.P.K).

References and Notes

1. Goedert M, Spillantini MG. Science 2006;314:777–781. [PubMed: 17082447]
2. Hardy J. J Alzheimers Dis 2006;9:151–153. [PubMed: 16914853]
3. Mathis CA, Klunk WE, Price JC, DeKosky ST. Arch Neurol 2005;62:196–200. [PubMed: 15710847]
4. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. N Engl J Med 2006;355:2652–2663. [PubMed: 17182990]
5. Mathis CA, Wang Y, Klunk WE. Current Pharmaceutical Design 2004;10:1469–1492. [PubMed: 15134570]
6. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung M-P, Houle S. American Journal of Geriatric Psychiatry 2004;12:584–595. [PubMed: 15545326]

7. Newberg AB, Wintering NA, Clark CM, Plossl K, Skovronsky D, Seibyl JP, Kung MP, Kung HF. J. Nucl. Med 2006;47:78.(Abstract # 220).
8. Small GW. J Geriatr Psychiatry Neurol 2006;19:180–185. [PubMed: 16880360]
9. Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, Greenberg C, Rebeck GW, Hyman BT, Greenberg SM, Frosch MP, Bacskai BJ. J Neurosci 2006;26:365–371. [PubMed: 16407531]
10. Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, Greenberg SM, Smith EE. Neurology 2006;67:83–87. [PubMed: 16832082]
11. Greenberg SM. N Engl J Med 2006;354:1451–1453. [PubMed: 16598043]
12. Kim DE, Schellingerhout D, Jaffer FA, Weissleder R, Tung CH. Journal of cerebral blood flow and metabolism 2005;25:226–233. [PubMed: 15678125]
13. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. Nuclear Medicine and Biology 2005;32:799–809. [PubMed: 16253804]
14. Chandra R, Oya S, Kung MP, Hou C, Jin LW, Kung HF. J Med Chem 2007;50:2415–2423. [PubMed: 17447752]
15. Stephenson KA, Chandra R, Zhuang ZP, Hou C, Oya S, Kung MP, Kung HF. Bioconjug Chem 2007;18:238–246. [PubMed: 17226978]
16. Kim H, Burghart A, Welch MB, Reibenspies J, Burgess K. Chemical Communications (Cambridge) 1999:1889–1890.
17. Wagner RW, Lindsey JS. Pure and Applied Chemistry 1996;68:1373–1380.
18. Chen J, Burghart A, Wan C-W, Thai L, Ortiz C, Reibenspies J, Burgess K. Tetrahedron Letters 2000;41:2303–2307.
19. Chen J, Burghart A, Derecskei-Kovacs A, Burgess K. Journal of Organic Chemistry 2000;65:2900–2906. [PubMed: 10814176]
20. Thoresen LH, Kim H, Welch MB, Burghart A, Burgess K. Synlett 1998:1276–1278.
21. Burghart A, Kim H, Welch MB, Thoresen LH, Reibenspies J, Burgess K, Bergstroem F, Johansson LBA. Journal of Organic Chemistry 1999;64:7813–7819.
22. Lee C-H, Lindsey JS. Tetrahedron 1994;50:11427–11440.
23. Baruah M, Qin W, Basaric N, De Borggraeve WM, Boens N. Journal of Organic Chemistry 2005;70:4152–4157. [PubMed: 15876108]
24. Ulrich G, Ziesel R. Journal of Organic Chemistry 2004;69:2070–2083. [PubMed: 15058955]
25. Sonogashira K, Tohda Y, Hagihara N. Tetrahedron Letters 1975:4467–4470.
26. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. Journal of Medicinal Chemistry 2005;48:5980–5988. [PubMed: 16162001]

Abbreviations

BODIPY, 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indecene; PEG, Polyethylene glycol.

Fig 1.
Examples of fluorophore, linkers and pharmacophores

Fig 2.
Excitation and emission (250 nM in Ethanol) spectra of **16**

Scheme 1. Synthesis of 4-bora-3a,4a-diaza-s-indacene (BODIPY) dye 1

Reagents and conditions: (a) p-Iodo benzaldehyde, TFA, DCM, 0°C, 52%, (b) p-chloroanil, DCM, 1 h, 85% (c) Et₃N, BF₃-Et₂O, MePH, 80°C, 88%, (d) 1.0 M BBr₃ in DCM, 0°C-rt, 4 h, 82%

Scheme 2. Preparation of terminal alkynes 10a and 10b

Reagents and conditions: (a) NaH, Propargyl Bromide, THF, 45% (n=3), 39% (n=10), (b) MsCl, Et₃N, DCM, 91% (n=2), 88% (n=10), (c) K₂CO₃, DMF, 100°C, 12 h, 82% (n=3), 78% (n=10)

Scheme 3.
Sonogashira coupling to synthesize compounds **11a–b**.

Scheme 4. Synthesis of Fluorescent probe 16

Reagents and conditions: (a) $\text{Pd(PPh}_3)_2\text{Cl}_2$, CuI, Et_3N , THF, 3 h, 51%, (b) **8a**, K_2CO_3 , DMF, 62%, (c) **1**, $\text{Pd(PPh}_3)_2\text{Cl}_2$, CuI, Et_3N , THF, 4h, 67%

Table 1Spectroscopic data for **11a**, **11b** and **16**

Compound	Solvent	$\lambda_{\text{max}}/\text{nm}$ (abs)	$\epsilon/\text{M}^{-1} \text{cm}^{-1}$	$\lambda_{\text{max}}/\text{nm}$ (em)
11a	Water	338	38,000	680
11b	Water	364	34,000	665
16	Water	345	35,000	678